Science Explorer Back to mapMap
Discussion
Company · Malmo · Sweden

BTB Pharma (Sweden)

btbpharma.comROR OpenAlex
Research works
3
▲ 485% vs 2018-21
Citations
38
12.5 per fractional work
Top-10% rate
18.3%
all institutions 10.0%
Open access
24%
world 40%
International
45%
world 18%
BTB Pharma (Sweden)

Not ranked overall: BTB Pharma (Sweden) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does BTB Pharma (Sweden) work in?

In all years, 47% of research at BTB Pharma (Sweden) is in Life Sciences, 37% in Health Sciences. Its largest fields are Biochemistry, Genetics and Molecular Biology (33%), Medicine (33%), Agricultural and Biological Sciences (7%). It does 1.3× the world's share of Life Sciences.

Life Sciences: 1 fractional works · 46.7% of its workBiochemistry, Genetics and Molecular Biology: 1 fractional works · 33.3% of its workAgricultural and Biological Sciences: 0 fractional works · 6.7% of its workPharmacology, Toxicology and Pharmaceutics: 0 fractional works · 6.7% of its workHealth Sciences: 1 fractional works · 36.7% of its workMedicine: 1 fractional works · 33.3% of its workNursing: 0 fractional works · 3.3% of its workPhysical Sciences: 0 fractional works · 10.0% of its workChemistry: 0 fractional works · 3.3% of its workComputer Science: 0 fractional works · 3.3% of its workMaterials Science: 0 fractional works · 3.3% of its workSocial Sciences: 0 fractional works · 6.7% of its workEconomics, Econometrics and Finance: 0 fractional works · 3.3% of its workSocial Sciences: 0 fractional works · 3.3% of its workALL ITS WORKBTB Pharma(Sweden)3fractional works, all years
Life Sciences47%Physical Sciences10%Health Sciences37%Social Sciences7%

Each ring splits the one inside it: the four domains of science, their fields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 10 fields, with their numbers
    1. Biochemistry, Genetics and Molecular Biology133.3%
    2. Agricultural and Biological Sciences06.7%
    3. Pharmacology, Toxicology and Pharmaceutics06.7%
    1. Medicine133.3%
    2. Nursing03.3%
    1. Chemistry03.3%
    2. Computer Science03.3%
    3. Materials Science03.3%
    1. Economics, Econometrics and Finance03.3%
    2. Social Sciences03.3%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Biochemistry, Genetics and Molecular Biology: 4.19× its world share, 0 worksBiochemistry, Geneti…Pharmacology, Toxicology and Pharmaceutics: 28.81× its world share, 0 worksPharmacology, Toxico…Chemistry: 7.76× its world share, 0 worksChemistryMaterials Science: 2.91× its world share, 0 worksMaterials ScienceMedicine: 1.64× its world share, 0 worksMedicineEconomics, Econometrics and Finance: 3.56× its world share, 0 worksEconomics, Econometr…Social Sciences: 0.48× its world share, 0 worksSocial Sciences1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Pharmacology, Toxicology and Pharmaceutics, 28.8×. Every wedge is a field page.

All 7 fields, with their numbers
  1. Pharmacology, Toxicology and Pharmaceutics28.81×0 works
  2. Chemistry7.76×0 works
  3. Biochemistry, Genetics and Molecular Biology4.19×0 works
  4. Economics, Econometrics and Finance3.56×0 works
  5. Materials Science2.91×0 works
  6. Medicine1.64×0 works
  7. Social Sciences0.48×0 works

What are the most cited papers from BTB Pharma (Sweden)?

The most cited paper from BTB Pharma (Sweden) is "The epidemiology and societal costs of myasthenia gravis in Norway: A non‐interventional study using national registry data" (Ingrid Engebretsen, Nils Erik Gilhus, Ivar Sønbø Kristiansen et al., 2024), with 23 citations. Next come "A Role for the Non-Receptor Tyrosine Kinase Abl2/Arg in Experimental Neuroinflammation" (10) and "AB1042 Dynamic contrast-enhanced magnetic resonance imaging in a randomized placebo-controlled rheumatoid arthritis trial – impact of applying joint coverage quality criteria" (0).

Most cited papers
#PaperReleasedCitations
1 The epidemiology and societal costs of myasthenia gravis in Norway: A non‐interventional study using national registry data Ingrid Engebretsen, Nils Erik Gilhus, Ivar Sønbø Kristiansen et al. · European Journal of Neurology Open access 7 Feb 2024 23
2 A Role for the Non-Receptor Tyrosine Kinase Abl2/Arg in Experimental Neuroinflammation Freja Aksel Jacobsen, Alexander N. Scherer, Jeppe Mouritsen et al. · Journal of Neuroimmune Pharmacology Open access 17 Mar 2018 10
3 AB1042 Dynamic contrast-enhanced magnetic resonance imaging in a randomized placebo-controlled rheumatoid arthritis trial – impact of applying joint coverage quality criteria MB Axelsen, Henning Bliddal, LTH Jacobssen et al. · Annals of the Rheumatic Diseases Open access Jun 2017 0
All 3 most cited papers, with filters and sorting

Which research topics does BTB Pharma (Sweden) publish most on?

By volume in 2022-now: Economic and Financial Impacts of Cancer, Ferrocene Chemistry and Applications, Biopolymer Synthesis and Applications and Heart Failure Treatment and Management.

Economic and Financial Impacts of Cancer: 0 fractional worksFerrocene Chemistry and Applications: 0 fractional worksBiopolymer Synthesis and…0Biopolymer Synthesis and Applications: 0 fractional worksHeart Failure Treatment and Management: 0 fractional worksPalliative Care and End-of-Life Issues: 0 fractional worksRNA Interference and Gene Delivery: 0 fractional worksAdvanced Drug Delivery Systems: 0 fractional worksNanoparticle-Based Drug …0Nanoparticle-Based Drug Delivery: 0 fractional worksLiver Disease Diagnosis and Treatment: 0 fractional worksPancasila Values in Education: 0 fractional works
Economics and EconometricsOrganic ChemistryMolecular BiologyCardiology and Cardiovascular Medicine5 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Economic and Financial Impacts of Cancer Economics and Econometrics 0 works
  2. 2 Ferrocene Chemistry and Applications Organic Chemistry 0 works
  3. 3 Biopolymer Synthesis and Applications Molecular Biology 0 works
  4. 4 Heart Failure Treatment and Management Cardiology and Cardiovascular Medicine 0 works
  5. 5 Palliative Care and End-of-Life Issues Public Health, Environmental and Occupational Health 0 works
  6. 6 RNA Interference and Gene Delivery Molecular Biology 0 works
  7. 7 Advanced Drug Delivery Systems Pharmaceutical Science 0 works
  8. 8 Nanoparticle-Based Drug Delivery Biomaterials 0 works
  9. 9 Liver Disease Diagnosis and Treatment Epidemiology 0 works
  10. 10 Pancasila Values in Education Education 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available24.1%not open75.9%

World: 40% of research is openly available.

with international co-authors45.4%domestic only54.6%

World: 18% is written across borders.

How has BTB Pharma (Sweden)'s research output changed?

Output in 2022-2025 was 485% higher than in 2018-2021.

still counting2010201520202025
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Malmo

All research institutions in Malmo

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about BTB Pharma (Sweden). Posts are plain text and can be reported.